文献速递姑息放疗与转移瘤胸部肿瘤放疗泌尿生殖与妇科肿瘤放疗

寡转移:过去、现在与未来

Oligometastasis: Past, Present, Future.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-01-01

本综述回顾了寡转移状态的临床数据与放疗证据,指出仅凭转移数目等临床标准判断寡转移存在明显局限,并强调分子特征(基因组、表观遗传与免疫特征)在联合临床指标时可提升预后判断能力。文章还讨论了分子靶点调控可能逆转多转移表型,及其对放疗试验与临床实践的意义。

要点

  • 临床标准(如转移数目)判断寡转移有局限,需分子特征补充预后信息。
  • 消融放疗在非小细胞肺癌与前列腺癌寡转移中显示癌症特异性结局获益。
  • 改进影像可检测隐匿转移,影响寡转移判断与试验入组。

核心结论

  • 仅用临床标准判断颅外真性寡转移存在明显局限,分子特征联合临床指标可改善预后判断。

研究设计与样本

  • 本文为综述,回顾寡转移假说的临床数据与放疗文献,并讨论基因组、表观遗传及免疫特征相关临床前与转化研究。

主要发现

  • 消融治疗寡转移在非小细胞肺癌与前列腺癌中显示癌症特异性结局获益。
  • 前瞻性消融放疗试验以转移数目这一最基础寡转移分类作为入组标准。
  • 基因组、表观遗传与免疫特征跨组织学类型联合经典临床相关因素可提升预后判断能力。
  • 部分分子靶点经治疗性调控有潜力将多转移表型逆转为寡转移表型。

关键数值与推荐

  • 当前及进行中的消融放疗前瞻性试验以转移数目作为寡转移分类与入组标准。

临床怎么用

  • 放疗临床判断寡转移应认识临床标准局限,关注分子特征对预后与试验设计的补充价值。
  • 改进影像检测隐匿转移可影响寡转移患者筛选与消融放疗决策。

局限性

  • 本文为综述,未报告原始研究的具体样本量、效应量或置信区间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In this review, we discuss the oligometastatic state, with a focus on its current and future relevance within the field of radiation therapy. We first outline the scope of the problem and the evolving understanding of metastatic disease existing along a spectrum. We then transition to a discussion of the clinical data that led to the formulation of the oligometastatic hypothesis, delving in some detail into the clinical factors associated with improved outcomes in the setting of local therapy-whether surgical or radiotherapeutic. In particular, we highlight the marked limitations of using clinical criteria alone to determine the absence or presence of true extracranial oligometastatic disease. After this, we briefly discuss the radiation therapy literature that has recently demonstrated benefits in cancer-specific outcomes with ablative treatment of oligometastatic disease. We emphasize data in the setting of non-small cell lung cancer and prostate cancer and briefly discuss the importance of our enhanced ability to detect occult metastatic disease with improved imaging technologies. After noting that resulted and ongoing prospective trials of ablative radiation therapy use the most rudimentary of oligometastatic classifiers-number of metastases-as their inclusion criteria, we transition to our core argument: a growing body of preclinical and translational work aims to refine the definition of oligometastatic disease using molecular features. We address genomic, epigenetic, and immunologic features that have, across histology, demonstrated an improved ability to prognosticate when combined with classic clinical correlates of oligometastatic disease. We also discuss studies that suggest particular molecular targets which, when manipulated for therapeutic purposes, have the potential to revert the polymetastatic phenotype to the oligometastatic one. We conclude with what we believe are the repercussions of this work for radiation therapy trials and clinical practice, and the importance of enriching and supporting these inquiries for the future of our field.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Gutiontov SI, Pitroda SP, Weichselbaum RR, et al. Oligometastasis: Past, Present, Future. Int J Radiat Oncol Biol Phys. 2020. PMID: 32976785. doi:10.1016/j.ijrobp.2020.02.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。